Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Expected outcomes of therapy

14 evidence topics · 16 sources

Summary: expected outcomes

AMPLITUDE is designed to assess the effect of inaxaplin on kidney function and proteinuria. In the phase 2a study, proteinuria decreased by day 15 and continued to decrease through week 13. The phase 2a study reported a mean UPCR change of -47.6% (95% CI -60.0 to -31.3) at week 13; its authors cite data from nearly 30,000 participants in which a 30% albuminuria reduction corresponded to a 27% lower risk of a composite kidney endpoint, and state as a hypothesis to be tested that a longer treatment period may prevent or slow progression to end-stage kidney disease. The AMPLITUDE final analysis uses eGFR slope after two years as the primary efficacy endpoint and time to a composite of a sustained eGFR decline of 30% or more, end-stage kidney disease, or death as the secondary endpoint, assessed when approximately 187 composite outcomes have occurred. Across CKD trials, each 30% reduction in albuminuria was associated with a 27% lower hazard of the clinical endpoint (41 treatment comparisons, 29,979 participants) or a 19% lower hazard (48 trials, 85,681 participants), and a 0.75 mL/min/1.73 m2 per year greater treatment effect on total GFR slope with a 23.3% lower hazard. In FSGS, a partial remission defined as a 40% proteinuria reduction with proteinuria below 1.5 g/g was associated with less progression (hazard ratio 0.30 at month 8), and a 2025 review found that further work is needed to define a treatment effect short of complete remission as an endpoint. The only AMKD-specific analysis found, a preprint of 128 participants, estimated that a 50% reduction in UACR at 12 months was associated with a 28% lower risk of a kidney composite endpoint. The sources reviewed give no estimate of the delay in kidney failure expected with inaxaplin; Vertex states that people with AMKD reach kidney failure at a median age of 45 years.